Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
Status and phase
Completed
Phase 3
Conditions
Diabetes Mellitus, Type 1
Diabetes
Treatments
Drug: insulin NPH
Drug: insulin detemir
Drug: insulin aspart
Details and patient eligibility
About
This trial is conducted in Europe.
The aim of this trial is to compare the efficacy and safety of insulin detemir and insulin NPH in adults with type 1 diabetes on blood glucose control.
Enrollment
114 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Duration of type 1 diabetes for at least 12 months
- BMI below 35 kg/m2
- HbA1c between 7.0-12.0%
- Current treatment with preprandial short acting insulin and insulin NPH once or twice daily for at least 6 months
- Fertile females must use acceptable method of contraception if there is any risk of pregnancy in the opinion of the Investigator
Exclusion criteria
- Known or suspected allergy to trial product or related products
- Previous participation in this trial
- Receipt of any investigational products within the last 2 months prior to this trial
- Drug or alcohol dependence
- Pregnancy, breast-feeding or intention of becoming pregnant
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
None (Open label)
Trial contacts and locations
18
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems